The test can be used to rapidly and accurately identify patients suffering from heart attacks, and to help identify low-risk patients who may be safely discharged, the firm said.
Individuals identified as needing homozygous FH evaluation will receive confirmatory genetic testing from Invitae and genetic counseling from Genome Medical.
As of January the project had returned 290 positive results for CDC Tier 1 conditions from 23,500 participants who had undergone exome sequencing.
The companies today launched four assays for the Chinese market for renal, liver, and cardiac testing for use on the Vitros 4600 and Vitros 5600 systems.
The partners anticipate developing tests that analyze clusters of biomarkers to detect cardiovascular disease, kidney disease, liver cancer, and other diseases.
The kit is for quantitatively measuring the percent of glycated hemoglobin, total cholesterol, high-density lipoprotein, triglycerides, and glucose.
The new services geared toward wellness testing enable patients to order test kits without visiting their doctor.
The company's technology uses a drop of blood applied to a biochip to provide a "complete panel" of diagnostic test results within 15 minutes.
The firm said that the funding could boost the presence of its cardiovascular test already on the market in Europe and support the development of others.
The firm said that it will use the proceeds to roll out a fully automated point-of-care platform that enables use of a broad panel of acute blood biomarkers.